Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain

Sickle Cell Patient’s AML Likely Unrelated To LentiGlobin

 
• By Alaric DeArment
  
Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
An analyses by bluebird bio probably rules out its gene therapy as the culprit behind a patient in its SCD study developing acute myeloid leukemia • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip